New TB cocktail aims to shorten treatment
NCT ID NCT07672405
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new combination of three drugs—sorfequiline, pretomanid, and linezolid—in 100 adults with newly diagnosed, drug-sensitive tuberculosis. Participants take the pills daily for 17 weeks. The goal is to see if the combo is safe and can clear the infection faster than standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sorfequiline, pretomanid, and linezolid
What this could lead to
If successful, this could lead to a shorter, simpler treatment regimen for drug-sensitive tuberculosis, potentially reducing side effects and improving cure rates.
What could go wrong
This is an early phase 2b trial with only 100 participants, so results may not apply to everyone. The drugs can cause side effects like nerve damage or vision problems, and the regimen may not work better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Durban International Clinical Research Site, Enhancing Care Foundation
Durban, Wentworth, 4052, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
INUKA Africa
Dar es Salaam, Tanzania
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Isango Lethemba TB Research Unit
Port Elizabeth, Bethelsdorp, 6200, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kilimanjaro Clinical Research Instuute
Moshi, Tanzania
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Madiberg Centre for Research
Brits, North West Provinvce, 0250, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mbeya Referral Hospital
Mbeya, Tanzania
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Instittute for Medical Research
Mwanza, Tanzania
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Setshaba Research Centre
Pretoria, Guateng, 0152, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Synergy Biomed Research Institute
East London, 5201, South Africa
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Aurum Institute, Rustenburg
Rustenburg, North West, 2999, South Africa
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Capetown Lung Institute
Cape Town, Mowbray, 7700, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact